Seifert J, Klause N, Stobbe J, Egbers H J
Department of General and Thoracic Surgery University of Kiel, Germany.
J Invest Surg. 1994 Mar-Apr;7(2):167-71. doi: 10.3109/08941939409015361.
To elucidate the safety of fibrin glue application, antibody formation against fibrinogen and thrombin was studied in rabbits. The pathophysiology of developed antibodies was tested by an intravenous challenge with both components and by related blood pressure measurements. All fibrin glue-treated animals developed antibodies against both components. The quantity of antibodies against thrombin (20.4 mg/mL) was higher than the quantity against fibrinogen (0.38 mg/mL). The intravenous challenge with both components resulted in a significant and long-lasting blood pressure decrease to about 50% of the control values, indicating that these antibodies can induce circulatory disorders by antigen-antibody reaction, activation of the complement cascade, and liberation of histamine. Since rabbits promptly produce antibodies against antigenic material and humans do not, the results of this investigation suggest that fibrin glue should be used with caution in humans.
为阐明应用纤维蛋白胶的安全性,在兔体内研究了针对纤维蛋白原和凝血酶的抗体形成情况。通过对两种成分进行静脉注射激发试验并测量相关血压,来检测所产生抗体的病理生理学变化。所有接受纤维蛋白胶治疗的动物均产生了针对这两种成分的抗体。针对凝血酶的抗体量(20.4毫克/毫升)高于针对纤维蛋白原的抗体量(0.38毫克/毫升)。对两种成分进行静脉注射激发试验导致血压显著且持久下降至对照值的约50%,这表明这些抗体可通过抗原-抗体反应、补体级联激活和组胺释放引发循环系统紊乱。由于兔会迅速产生针对抗原性物质的抗体而人类不会,本研究结果提示在人类中使用纤维蛋白胶应谨慎。